Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227818 · ClinicalTrials.gov registry record · Phase 3
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
A Phase 3 study, sponsored by Neurocrine Biosciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 560
- Enrollment target
NCT07227818: Recruiting Phase 3 study, sponsored by Neurocrine Biosciences.
NCT07227818 is a Phase 3 study that is actively recruiting participants, run by Neurocrine Biosciences. The registered enrollment target is 560 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07227818, a Phase 3 study, is actively recruiting participants, sponsored by Neurocrine Biosciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 560 participants
- Enrollment target
Study Summary
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
Interventions
- DRUG Placebo
- DRUG NBI-1117568
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2029-07 |
| Phase | Phase 3 |
What NCT07227818 shows while recruiting
NCT07227818 is an interventional study that assigns participants to a tested intervention. The registered 560 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07227818 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07227818 about?
NCT07227818 is a clinical study titled "Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia". The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
What is the current status of trial NCT07227818?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 560 participants. The study started on 2025-12-16. Estimated completion is 2029-07.
What interventions are being tested in trial NCT07227818?
The interventions under investigation include: Placebo (DRUG), NBI-1117568 (DRUG).
Who is sponsoring clinical trial NCT07227818?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07227818's enrollment target sits among peer trials
560 671st of 2000 higher than 1,328 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
- NCT06001541 · 560 participants · NA
Web-based Program to Improve Self-management Among Veterans-caregiver Dyads
- NCT06246916 · 560 participants · Phase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI